CY1106115T1 - Προσδιορισμος κινασης αναπλαστικου λεμφωματος, αντιδραστηρια και συνθεσεις αυτης - Google Patents

Προσδιορισμος κινασης αναπλαστικου λεμφωματος, αντιδραστηρια και συνθεσεις αυτης

Info

Publication number
CY1106115T1
CY1106115T1 CY20061100923T CY061100923T CY1106115T1 CY 1106115 T1 CY1106115 T1 CY 1106115T1 CY 20061100923 T CY20061100923 T CY 20061100923T CY 061100923 T CY061100923 T CY 061100923T CY 1106115 T1 CY1106115 T1 CY 1106115T1
Authority
CY
Cyprus
Prior art keywords
reagents
compositions
determination
anaplastic lymphoma
lymphoma kinase
Prior art date
Application number
CY20061100923T
Other languages
English (en)
Inventor
Lorenzo A. Pinna
Arianna Donella-Deana
Oriano Marin
Luca Mologni
Rosalind Gunby
Carlo Gambacorti-Passerini
Leonardo Scapozza
Original Assignee
Istituto Nazionale Per Lo Studio E La Cura Dei Tumori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Nazionale Per Lo Studio E La Cura Dei Tumori filed Critical Istituto Nazionale Per Lo Studio E La Cura Dei Tumori
Publication of CY1106115T1 publication Critical patent/CY1106115T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Παρουσιάζονται μέθοδοι για την ανίχνευση της δράσης της κινάσης τυροσίνης ALK και για την ταυτοποίηση ενώσεων που τροποποιούν τη δράση της ALK, τα πεπτιδικά υποστρώματα, τα αντιδραστήρια και οι συνθέσεις αυτών.
CY20061100923T 2003-03-07 2006-07-04 Προσδιορισμος κινασης αναπλαστικου λεμφωματος, αντιδραστηρια και συνθεσεις αυτης CY1106115T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03005186A EP1454992B1 (en) 2003-03-07 2003-03-07 Anaplastic lymphoma kinase assay, reagents and compositions thereof

Publications (1)

Publication Number Publication Date
CY1106115T1 true CY1106115T1 (el) 2011-06-08

Family

ID=32798804

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100923T CY1106115T1 (el) 2003-03-07 2006-07-04 Προσδιορισμος κινασης αναπλαστικου λεμφωματος, αντιδραστηρια και συνθεσεις αυτης

Country Status (15)

Country Link
US (1) US20070031907A1 (el)
EP (1) EP1454992B1 (el)
JP (1) JP2006519800A (el)
CN (1) CN100345978C (el)
AT (1) ATE328112T1 (el)
CA (1) CA2518094A1 (el)
CY (1) CY1106115T1 (el)
DE (1) DE60305634T2 (el)
DK (1) DK1454992T3 (el)
ES (1) ES2263862T3 (el)
HK (1) HK1068154A1 (el)
IL (1) IL170669A0 (el)
PT (1) PT1454992E (el)
SI (1) SI1454992T1 (el)
WO (1) WO2004079326A2 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2561406T3 (es) 2006-04-14 2016-02-26 Cell Signaling Technology, Inc. Defectos de genes y quinasa ALK mutante en tumores sólidos humanos
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
EP2107054A1 (en) 2008-04-01 2009-10-07 Università Degli Studi Di Milano - Bicocca Antiproliferative compounds and therapeutic uses thereof
EP2274288A2 (en) 2008-04-24 2011-01-19 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
EP2161271A1 (en) 2008-09-08 2010-03-10 Università Degli Studi Di Milano - Bicocca Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl
WO2010085597A1 (en) 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
US9126931B2 (en) * 2009-06-10 2015-09-08 Chugai Seiyaku Kabushiki Kaisha Tetracyclic compound
CN101955995B (zh) * 2010-06-17 2013-06-26 江苏迈迪基因生物科技有限公司 淋巴瘤相关的融合基因的诊断试剂盒
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
WO2012023597A1 (ja) 2010-08-20 2012-02-23 中外製薬株式会社 ４環性化合物を含む組成物
EP2847353B1 (en) 2012-05-10 2022-01-19 The General Hospital Corporation Methods for determining a nucleotide sequence
TR201815994T4 (tr) 2012-09-25 2018-11-21 Chugai Pharmaceutical Co Ltd Ret inhibitörü.
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
US10450597B2 (en) 2014-01-27 2019-10-22 The General Hospital Corporation Methods of preparing nucleic acids for sequencing
CA2946268A1 (en) 2014-04-25 2015-10-29 Chugai Seiyaku Kabushiki Kaisha Crystal of tetracyclic compound
KR102412321B1 (ko) 2014-04-25 2022-06-22 추가이 세이야쿠 가부시키가이샤 4환성 화합물을 고용량 함유하는 제제
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體
RU2740261C2 (ru) 2015-01-16 2021-01-12 Чугаи Сейяку Кабусики Кайся Комбинированное лекарственное средство
CN109937254B (zh) 2016-09-15 2023-05-30 阿谢尔德克斯有限责任公司 核酸样品制备方法
CA3037190A1 (en) 2016-09-15 2018-03-22 ArcherDX, Inc. Methods of nucleic acid sample preparation for analysis of cell-free dna
EP4198140A1 (en) 2016-11-02 2023-06-21 ArcherDX, LLC Methods of nucleic acid sample preparation for immune repertoire sequencing
WO2020050241A1 (ja) 2018-09-04 2020-03-12 中外製薬株式会社 ４環性化合物の製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05126833A (ja) * 1991-10-31 1993-05-21 Tosoh Corp チロシンキナ−ゼ活性の免疫化学的測定法及びそのキツト
AU4281393A (en) * 1992-04-10 1993-11-18 Dana-Farber Cancer Institute, Inc. Activation-state-specific phosphoprotein immunodetection
ES2136103T3 (es) * 1992-06-22 1999-11-16 Kyowa Hakko Kogyo Kk Procedimiento para la preparacion de derivados de estaurosporina.
GB9314271D0 (en) * 1993-07-09 1993-08-18 Inst Of Cancer The Research Cell growth factor receptors
US6001621A (en) * 1993-11-23 1999-12-14 Genetech, Inc. Protein tyrosine kinases
CA2175892C (en) * 1993-11-23 2000-03-07 Paul J. Godowski Kinase receptor activation assay
US5529925A (en) * 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US5763198A (en) * 1994-07-22 1998-06-09 Sugen, Inc. Screening assays for compounds
US5759787A (en) * 1996-08-26 1998-06-02 Tularik Inc. Kinase assay
CA2288221A1 (en) * 1997-04-28 1998-11-05 Sugen, Inc. Diagnosis and treatment of phosphatase 0r kinase-related disorders
US6806266B1 (en) * 1999-07-13 2004-10-19 Kyowa Hakko Kogyo Co., Ltd. Staurosporin derivatives

Also Published As

Publication number Publication date
JP2006519800A (ja) 2006-08-31
CN1756850A (zh) 2006-04-05
ATE328112T1 (de) 2006-06-15
WO2004079326A2 (en) 2004-09-16
US20070031907A1 (en) 2007-02-08
DE60305634T2 (de) 2006-09-21
HK1068154A1 (en) 2005-04-22
WO2004079326A3 (en) 2004-12-09
EP1454992B1 (en) 2006-05-31
IL170669A0 (en) 2011-08-01
SI1454992T1 (sl) 2006-10-31
EP1454992A1 (en) 2004-09-08
DK1454992T3 (da) 2006-10-02
ES2263862T3 (es) 2006-12-16
CN100345978C (zh) 2007-10-31
PT1454992E (pt) 2006-09-29
DE60305634D1 (de) 2006-07-06
CA2518094A1 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
CY1106115T1 (el) Προσδιορισμος κινασης αναπλαστικου λεμφωματος, αντιδραστηρια και συνθεσεις αυτης
ATE420879T1 (de) Indolizine als kinaseproteinhemmer
CY1113837T1 (el) Αμινοετεροαρυλ ενωσεις ως αναστολεις κινασης πρωτεϊνης
DE602004001227D1 (de) Nukleinsäure-biosensor
NO20044597L (no) Kjemiske forbindelser
CY1114554T1 (el) Ινδαζολια, βενζοτριαζολια και ν-αναλογα αυτων ως αναστολεις p38 κινασης
ATE480643T1 (de) Homogener nachweis von analyten
WO2005028443A3 (en) Protein tyrosine kinase enzyme inhibitors
NO20005224L (no) BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse
DE60230672D1 (de) Nukleinsäureanreicherung
DE60140120D1 (de) Toxizitätstypisierung unter verwendung von leberstammzellen
NO20023705D0 (no) Bestemmelse av art/type for et underjordisk reservoar
WO2004062475A3 (en) Fluorescent assays for protein kinases
ATE424560T1 (de) Marker für neuromyelitis optica
EA200300880A1 (ru) Способ детекции нуклеотидного полиморфизма
CY1105980T1 (el) Βελτιωμενη διαδικασια παρασκευης υδροβρωμικου αλατος του αλφα-πολυμορφικου ελετριπτανιου
DE60316984D1 (de) Benzoylsulfonamide als antitumor-mittel
BR0311318A (pt) Inibidores de peptìdeo desformilase
CY1111432T1 (el) Τετραϋδροκινολινες για χρηση ως διαμορφωτες της μιτοτικης κινητικης πρωτεϊνης eg5
AU2003223634A1 (en) Peptide deformylase inhibitors
DK1664093T3 (da) Antitumorforbindelser baseret på kahalalid F
NO20033921L (no) Inhibitor av monoaminopptak
EA200600609A1 (ru) Производные имидазопиридина в качестве ингибиторов индуцируемой no-синтазы
ATE370964T1 (de) Isoliertes fluoreszierendes protein aus clytia gregaria cgfp, sowie dessen verwendung
AU2002258437A1 (en) Peptide deformylase inhibitors